API Holdings, the parent entity of PharmEasy and Thyrocare, has repaid its entire ₹1,050 crore term loan. The company also reported a narrower loss and positive operating profit for Q1 FY27. While this improves the balance sheet, the company remains unlisted and is focused on sustainable growth.
API Holdings, the parent company of the online pharmacy platform PharmEasy and the diagnostic chain Thyrocare, has successfully eliminated its entire term loan debt. The company announced it has repaid ₹1,050 crore in outstanding debt, reaching a debt-free status as of August 2026. This move follows a period of financial restructuring aimed at reducing the burden on the company’s balance sheet.
Financial performance for the first quarter of fiscal year 2027 shows clear signs of improvement. The company reported a net loss of ₹29.6 crore, which is a significant reduction compared to the ₹145.4 crore loss in the same period last year. Operating profit, or EBITDA, turned positive at ₹39.3 crore, compared to an operating loss of ₹12.8 crore in the year-ago quarter. Revenue also grew by 10% to ₹1,754 crore, driven by contributions from both its business-to-business medicine distribution and consumer-facing pharmacy operations.
The repayment of the ₹1,050 crore loan was funded through a combination of internal cash generation and the sale of a 9.90% stake in Thyrocare Technologies. This transaction was executed through Docon Technologies, the promoter entity. Following this stake sale, the promoter group retains a majority 51.02% interest in Thyrocare. Crucially, the debt repayment has also led to the release of all shares that were previously pledged as security for the loans, leaving the promoter’s stake in Thyrocare unencumbered.
While this development marks a stabilization in the company's financial structure, it is important for observers to note that API Holdings is an unlisted public limited company. Because it is not traded on public stock exchanges like the NSE or BSE, there is no formal market for its shares, which creates liquidity risk for those holding equity in the firm. The company had previously attempted to launch an Initial Public Offering (IPO) in 2022 but withdrew those plans due to broader market conditions at the time.
Going forward, the company's ability to maintain this positive trajectory will depend on its capacity to sustain profitability across its core business segments, including the performance of PharmEasy and its hospital supply chain arm, Aknamed. The management’s focus has shifted from aggressive, debt-funded expansion to achieving consistent, sustainable profitability. Investors and industry observers will likely monitor whether these operational improvements continue in the coming quarters without the pressure of significant interest payments.